All In Biotech

Drug Trial Radar · NCT04202965

PTG-300 in Subjects With Hereditary Hemochromatosis

Open-label Study of PTG-300 in Subjects With Hereditary Hemochromatosis

Last checked: Nov 20, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

16

Actual

Start

Mar 19, 2020

Primary completion

Oct 6, 2021

Study completion Feb 15, 2022

Sponsor

Lead sponsor
Protagonist Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be conducted at multiple sites and every patient will get treated with PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult hereditary hemochromatosis patients.

Conditions

  • Hereditary Hemochromatosis

Interventions

  • PTG-300Drug

    Active treatment with PTG-300 injected subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effect of PTG-300 on Transferrin SaturationTime frame: Week 24 (or End of Treatment if treated for less than 24 weeks)
  2. Effect of PTG-300 on Serum IronTime frame: Week 24 (or End of Treatment if treated for less than 24 weeks)

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • Protagonist Investigational Site

    Fayetteville, Georgia

  • Protagonist Investigational Site

    Bethesda, Maryland

  • Protagonist Investigational Site

    Charlotte, North Carolina

  • Protagonist Investigational Site

    Conroe, Texas

  • Protagonist Investigational Site

    Dallas, Texas

  • Protagonist Investigational Site

    Houston, Texas

  • Protagonist Investigational Site

    Houston, Texas

  • Protagonist Investigational Site

    Richmond, Virginia

  • Protagonist Investigational Site

    Seattle, Washington

  • Protagonist Investigational Site

    Halifax, Nova Scotia, Canada

  • Protagonist Investigational Site

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.